组蛋白去乙酰化酶抑制剂在癌症表观遗传学治疗中的新临床进展。
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
机构信息
Division of Hematology/Oncology, New York Medical College, Valhalla, NY 10595, USA.
出版信息
J Hematol Oncol. 2009 Jun 1;2:22. doi: 10.1186/1756-8722-2-22.
Abstract
DNA methylation and histone acetylation are two well known epigenetic chromatin modifications. Epigenetic agents leading to DNA hypomethylation and histone hyperacetylation have been approved for treatment of hematological disorders. The first histone deacetylase inhibitor, vorinostat, has been licensed for cutaneous T cell lymphoma treatment. More than 11 new epigenetic agents are in various stages of clinical development for therapy of multiple cancer types. In this review we summarize novel histone deacetylase inhibitors and new regimens from clinical trials for epigenetic therapy of cancer.
摘要
DNA 甲基化和组蛋白乙酰化是两种众所周知的表观遗传染色质修饰。导致 DNA 低甲基化和组蛋白高乙酰化的表观遗传药物已被批准用于治疗血液系统疾病。第一个组蛋白去乙酰化酶抑制剂伏立诺他已被批准用于治疗皮肤 T 细胞淋巴瘤。目前有 11 多种新的表观遗传药物处于不同的临床开发阶段，用于治疗多种癌症类型。在这篇综述中，我们总结了新型组蛋白去乙酰化酶抑制剂和临床试验中的新方案，用于癌症的表观遗传治疗。
相似文献
1
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
J Hematol Oncol. 2009 Jun 1;2:22. doi: 10.1186/1756-8722-2-22.
2
Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
Anticancer Drugs. 2010 Oct;21(9):805-13. doi: 10.1097/CAD.0b013e32833dad91.
3
Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
Epigenomics. 2010 Jun;2(3):457-65. doi: 10.2217/epi.10.20.
4
Epigenetic therapy of cancer with histone deacetylase inhibitors.
J Cancer Res Ther. 2014 Jul-Sep;10(3):469-78. doi: 10.4103/0973-1482.137937.
5
Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of .
Clin Epigenetics. 2017 Jun 8;9:62. doi: 10.1186/s13148-017-0359-x. eCollection 2017.
6
Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Curr Protein Pept Sci. 2018;19(3):333-340. doi: 10.2174/1389203718666170106101133.
7
[Targeted epigenetic therapy of cancer. Achievements and perspectives].
Cir Cir. 2012 Sep-Oct;80(5):470-80.
8
Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
Curr Drug Metab. 2007 May;8(4):383-93. doi: 10.2174/138920007780655397.
9
HDAC Inhibitors.
Methods Mol Biol. 2016;1436:281-303. doi: 10.1007/978-1-4939-3667-0_19.
10
Pharmacological targeting of the cancer epigenome.
Nat Cancer. 2024 Jun;5(6):844-865. doi: 10.1038/s43018-024-00777-2. Epub 2024 Jun 27.
引用本文的文献
1
Acetyl-CoA Carboxylase Inhibitor CP640.186 Increases Tubulin Acetylation and Impairs Thrombin-Induced Platelet Aggregation.
Int J Mol Sci. 2021 Dec 4;22(23):13129. doi: 10.3390/ijms222313129.
2
Cancer's epigenetic drugs: where are they in the cancer medicines?
Pharmacogenomics J. 2020 Jun;20(3):367-379. doi: 10.1038/s41397-019-0138-5. Epub 2019 Dec 10.
3
Emerging roles of Myc in stem cell biology and novel tumor therapies.
J Exp Clin Cancer Res. 2018 Jul 27;37(1):173. doi: 10.1186/s13046-018-0835-y.
4
Critical role of the HDAC6-cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect.
Nat Commun. 2017 Nov 27;8(1):1786. doi: 10.1038/s41467-017-01690-2.
5
Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment.
J Hematol Oncol. 2017 Mar 9;10(1):67. doi: 10.1186/s13045-017-0436-9.
6
Epigenetics and Cellular Metabolism.
Genet Epigenet. 2016 Sep 25;8:43-51. doi: 10.4137/GEG.S32160. eCollection 2016.
7
Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis.
BMC Med. 2016 Jun 15;14:89. doi: 10.1186/s12916-016-0635-1.
8
Combination of Salermide and Cholera Toxin B Induce Apoptosis in MCF-7 but Not in MRC-5 Cell Lines.
Int J Prev Med. 2013 Dec;4(12):1402-13.
9
Epigenetic therapy in human choriocarcinoma.
Cancers (Basel). 2010 Sep 10;2(3):1683-8. doi: 10.3390/cancers2031683.
10
Preclinical cancer chemoprevention studies using animal model of inflammation-associated colorectal carcinogenesis.
Cancers (Basel). 2012 Jul 16;4(3):673-700. doi: 10.3390/cancers4030673.
本文引用的文献
1
Clinical advances in hypomethylating agents targeting epigenetic pathways.
Curr Cancer Drug Targets. 2010 Aug;10(5):539-45. doi: 10.2174/156800910791517217.
2
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
Eur J Cancer. 2010 Jun;46(9):1573-9. doi: 10.1016/j.ejca.2010.02.047. Epub 2010 Mar 19.
3
Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
Clin Lymphoma Myeloma. 2009 Dec;9(6):412-6. doi: 10.3816/CLM.2009.n.082.
4
A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma.
Ann Hematol. 2010 Feb;89(2):185-90. doi: 10.1007/s00277-009-0793-8. Epub 2009 Jul 25.
5
De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc.
Int J Oncol. 2008 Aug;33(2):375-80.
6
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Melanoma Res. 2008 Aug;18(4):274-8. doi: 10.1097/CMR.0b013e328307c248.
7
Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor.
Expert Opin Investig Drugs. 2008 Aug;17(8):1247-54. doi: 10.1517/13543784.17.8.1247.
8
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
Clin Cancer Res. 2008 Jul 15;14(14):4517-25. doi: 10.1158/1078-0432.CCR-07-1461. Epub 2008 Jun 25.
9
Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways.
J Hematol Oncol. 2008 Jun 9;1:6. doi: 10.1186/1756-8722-1-6.
10
Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.
J Med Chem. 2008 Jul 24;51(14):4072-5. doi: 10.1021/jm800251w. Epub 2008 Jun 21.
Zotero 插件